Baseline factors affecting the efficacy of troglitazone on plasma glucose in Japanese patients with non-insulin-dependent diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 41, Issue 2, 1998, Pages 121-129

  Kuzuya, Takeshi ^a   Kosaka, Kinori ^b   Akanuma, Yasuo ^c   Shigeta, Yukio ^d   Kaneko, Toshio ^e  

^a Shioya General Hospital   (Japan)

^b TORANOMON HOSPITAL   (Japan)

^c INSTITUTE FOR ADULT DISEASES   (Japan)

^d SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^e YAMAGUCHI ROSAI HOSPITAL   (Japan)

Author keywords

Effect of troglitazone; NIDDM; Obesity; Troglitazone

Indexed keywords

C PEPTIDE; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DIABETES CONTROL; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; JAPAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME;

AGED; BLOOD GLUCOSE; CHROMANS; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; LIPIDS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; THIAZOLES; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 0032143711     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(98)00069-2     Document Type: Article

References (22)

1. DeFronzo R.A. Pathogenesis of Type 2 (non-insulin-dependent) diabetes mellitus: a balanced overview. Diabetologia. 35:1992;389-397.
2. Taylor S.I., Accili D., Imai Y. Insulin resistance or insulin deficiency: which is the primary cause of NIDDM? Diabetes. 43:1994;735-740.
3. Saltieland A.R., Horikoshi H. Thiazolidinediones are novel insulin-sensitizing agents. Curr. Opin. Endocrinol. Diab. 2:1995;341-347.
4. Fujiwara T., Yoshioka S., Yoshioka T., Ushiyama I., Horikoshi H. Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes. 37:1988;1549-1558.
5. Iwamoto Y., Kosaka K., Kuzuya T., Akanuma Y., Shigeta Y., Kaneko T. A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diab. Care. 19:1996;151-156.
6. Iwamoto Y., Kosaka K., Kuzuya T., Akanuma Y., Shigeta Y., Kaneko T. Effect of combination therapy of troglitazone and sulphonylureas in patients with type 2 diabetes who were poorly controlled by sulphonylurea therapy alone. Diab. Med. 13:1996;365-370.
7. Kuzuya T., Kosaka K., Akanuma Y., Shigeta Y., Kaneko T., Shimizu N. One-year clinical trial of a new oral hypoglycemic agent, CS-045, in NIDDM patients. Diabetologia (Abstr.). 37(Suppl. 1):1994;63.
8. Kuzuya T., Iwamoto Y., Kosaka K. et al. A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin-dependent diabetes mellitus. Diab. Res. Clin. Pract. 11:1991;147-154.
9. Shigeta Y., Kobayashi M., Kosaka K. et al. Clinical evaluation of a new oral hypoglycemic agent, CS-045, in uncontrolled non-insulin-dependent diabetic patients. Diabetes (Abstr.). 41 (Suppl. 1):1992;76A.
10. Akanuma Y., Kosaka K., Shigeta Y., Kuzuya T., Kaneko T., Shimizu N. Clinical evaluation of a new oral hypoglycemic agent, CS-045, in Type 2 diabetes. Diabetologia (Abstr.). 35(Suppl. 1):1992;63.
11. Yamada N., Akanuma Y., Murase T. et al. Clinical evaluation of a new oral hypoglycemic drug, CS-045, in patients with non-insulin-dependent diabetes mellitus accompanying hypertriglyceridemia. J. Clin. Therap. Med. 9(Suppl. 3):1993;165-178. (in Japanese).
12. Nakano K., Yasuda T., Kitagawa Y. et al. Clinical evaluation of a new oral hypoglycemic drug, CS-045, on daily profile of blood glucose in patients with non-insulin-dependent diabetes mellitus. J. Clin. Ther. Med. 9(Suppl. 3):1993;151-164. (in Japanese).
13. Ikeda Y., Yamada H., Ohno M., Tajima N., Sakamoto Y. Clinical evaluation of a new oral hypoglycemic drug, CS-045, in patients with obese non-insulin-dependent diabetes mellitus. J. Clin. Ther. Med. 9(Suppl. 3):1993;179-190. (in Japanese).
14. Seino Y., Ishida H., Kurahachi H. et al. Clinical evaluation of a new oral hypoglycemic drug, CS-045, in patients with non-insulin-dependent diabetes mellitus poorly controlled with sulfonylureas - study with 100 mg tablet. J. Clin. Ther. Med. 9(Suppl. 3):1993;191-203. (in Japanese).
15. Maruyama H., Hirose H., Simada A., Wainai H., Nishino M., Saruta T. Clinical evaluation of a new oral hypoglycemic drug, CS-045, in patients with non-insulin-dependent diabetes mellitus - study with 100 mg tablet. J. Clin. Ther. Med. 9(Suppl. 3):1993;205-215. (in Japanese).
16. Mallows C.L. Some comments on Cp. Technometrics. 15:1973;661-675.
17. Iwamoto Y., Kuzuya T., Matsuda A. et al. Effect of new oral antidiabetic agent, CS-045, on glucose tolerance and insulin secretion in patients with NIDDM. Diab. Care. 14:1991;1083-1086.
18. J.M. Olefsky, J.M. Molina, Insulin resistance in man, in: H. Rifkin, D. Porte Jr. (Eds.), Ellenberg and Rifkin's Diabetes Mellitus: Theory and Practice, 4th ed., Elsevier, New York, 1990, pp. 121-153.
19. M. Chen, R.N. Bergman, G. Pacini, D. Porte Jr., Pathogenesis of age-related glucose intolerance in man: insulin resistance and decreased β-cell function, J. Clin. Endocrinol. Metab. 60 (1985) 13-20.
20. De Fronzo R.A Glucose intolerance and aging. Diab. Care. 4:1981;493-501.
21. Jackson R.A. Mechanisms of age-related glucose intolerance. Diab. Care. 13(Suppl. 2):1990;9-19.
22. Shibata H., Nii S., Kobayashi M. et al. Phase I study of a new hypoglycemic agent, CS-045, in healthy volunteers. J. Clin. Ther. Med. 9:1993;1519-1537. (in Japanese).